BioLineRx to Present at Biotech Showcase Conference in San Francisco
(Logo: http://photos.prnewswire.com/prnh/20130730/630769 )
The BioLineRx presentation is scheduled to start at
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in
BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's
Contact:
jdrumm@tiberend.com
(212) 375-2664
Andrew Mielach
amielach@tiberend.com
(212) 375-2694
Or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il
SOURCE BioLineRx